Journal of Shanghai Jiao Tong University (Medical Science) >

2024 , Vol. 44 >Issue 7: 801 - 813

DOI: https://doi.org/10.3969/j.issn.1674-8115.2024.07.001

Innovative research team achievement column

Expression of cancer-testis antigen SPANXB and its mechanism in affecting hepatocellular carcinoma progress

  • Yu XUE ,
  • Hailong ZHANG ,
  • Ming LEI
Expand
  • 1.Shanghai Institute of Precision Medicine, Shanghai Ninth People′s Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 200125, China
    2.Institute of Translational Medicine, Shanghai Jiao Tong University, Shanghai 200240, China
ZHANG Hailong, E-mail: zhanghailong@sjtu.edu.cn.
LEI Ming, E-mail: leim@shsmu.edu.cn

Received date: 2023-12-18

  Accepted date: 2024-04-17

  Online published: 2024-07-28

Supported by

National Key Research and Development Program of China(2018YFA0107004)

Fold

Abstract

Objective ·To analyze the expression of cancer-testis antigen (CTA) family member SPANXB (sperm protein associated with the nucleus on the X chromosome B) in liver cancer and its correlation with the prognosis of liver cancer patients, and to explore the impact of SPANXB on liver cancer cell proliferation and its potential mechanism. Methods ·By using liver cancer sample data from the cancer genome atlas (TCGA) database, the expression of SPANXB in liver cancer tissue and its correlation with patient survival were analyzed. By constructing stable knockdown of SPANXB and stable overexpression of SPANXB in liver cancer cell lines, the effects of SPANXB on liver cancer cell proliferation were evaluated with live cell imaging experiments, EdU cell proliferation experiments and plate clone formation experiments. The regulatory pathways of SPANXB in liver cancer cell proliferation were explored through RNA-sequence (RNA-seq), and the effect of SPANXB on liver cancer cell cycle was validated through cell cycle experiments. Immunoprecipitation-mass spectrometry (IP-MS) was used to explore the proteins that interacted with SPANXB, and co-immunoprecipitation (Co-IP) was used to verify their interaction. Results ·The expression of SPANXB mRNA in liver cancer tissues was higher than that in normal tissues (P=0.003), and was negatively correlated with the survival of liver cancer patients. Stable knockdown of SPANXB could reduce the proliferation and clone formation ability of liver cancer cells, while stable overexpression of SPANXB could promote these processes. The analysis results of RNA-seq showed that knockdown of SPANXB could lead to downregulation of DNA replication and G1/S cell cycle transition-related pathways. The results of cell cycle experiments showed that knockdown of SPANXB could result in changes in the liver cancer cell cycle. The results of IP-MS and Co-IP showed that SPAXNB interacted with cell cycle-related proteins such as mitotic arrest defect 2-like protein 1 (MAD2L1) and WD repeat domain 5 (WDR5). Conclusion ·The high expression of SPANXB is negatively correlated with the prognosis of liver cancer. SPANXB may regulate the cell cycle and enhance the proliferation activity of liver cancer cells by interacting with MAD2L1 and WDR5.

Key words： cancer-testis antigen (CTA); sperm protein associated with the nucleus on the X chromosome B (SPANXB); liver cancer; cell cycle

Cite this article

Yu XUE , Hailong ZHANG , Ming LEI . Expression of cancer-testis antigen SPANXB and its mechanism in affecting hepatocellular carcinoma progress[J]. Journal of Shanghai Jiao Tong University (Medical Science), 2024 , 44(7) : 801 -813 . DOI: 10.3969/j.issn.1674-8115.2024.07.001

References

1 SCANLAN M J, GURE A O, JUNGBLUTH A A, et al. Cancer/testis antigens: an expanding family of targets for cancer immunotherapy[J]. Immunol Rev, 2002, 188: 22-32.
2 PINEDA C T, RAMANATHAN S, FON TACER K, et al. Degradation of AMPK by a cancer-specific ubiquitin ligase[J]. Cell, 2015, 160(4): 715-728.
3 LI F, ZHAO F S, LI M, et al. Decreasing New York esophageal squamous cell carcinoma 1 expression inhibits multiple myeloma growth and osteolytic lesions[J]. J Cell Physiol, 2020, 235(3): 2183-2194.
4 GREVE K B, LINDGREEN J N, TERP M G, et al. Ectopic expression of cancer/testis antigen SSX2 induces DNA damage and promotes genomic instability[J]. Mol Oncol, 2015, 9(2): 437-449.
5 MIZUSHIMA E, TSUKAHARA T, EMORI M, et al. Osteosarcoma-initiating cells show high aerobic glycolysis and attenuation of oxidative phosphorylation mediated by LIN28B[J]. Cancer Sci, 2020, 111(1): 36-46.
6 ZENDMAN A J, CORNELISSEN I M, WEIDLE U H, et al. CTp11, a novel member of the family of human cancer/testis antigens[J]. Cancer Res, 1999, 59(24): 6223-6229.
7 HSIAO Y J, SU K Y, HSU Y C, et al. SPANXA suppresses EMT by inhibiting c-JUN/SNAI2 signaling in lung adenocarcinoma[J]. Oncotarget, 2016, 7(28): 44417-44429.
8 WANG X W, JU S H, CHEN Y, et al. Hypomethylation-activated cancer-testis gene SPANXC promotes cell metastasis in lung adenocarcinoma[J]. J Cell Mol Med, 2019, 23(11): 7261-7267.
9 ZHU F, BO H, LIU G M, et al. SPANXN2 functions a cell migration inhibitor in testicular germ cell tumor cells[J]. PeerJ, 2020, 8: e9358.
10 MAINE E A, WESTCOTT J M, PRECHTL A M, et al. The cancer-testis antigens SPANX-A/C/D and CTAG2 promote breast cancer invasion[J]. Oncotarget, 2016, 7(12): 14708-14726.
11 LAZAR I, FABRE B, FENG Y M, et al. SPANX control of lamin A/C modulates nuclear architecture and promotes melanoma growth[J]. Mol Cancer Res, 2020, 18(10): 1560-1573.
12 ALMANZAR G, OLKHANUD P B, BODOGAI M, et al. Sperm-derived SPANX-B is a clinically relevant tumor antigen that is expressed in human tumors and readily recognized by human CD4+ and CD8+ T cells[J]. Clin Cancer Res, 2009, 15(6): 1954-1963.
13 PETRICK J L, FLORIO A A, ZNAOR A, et al. International trends in hepatocellular carcinoma incidence, 1978-2012[J]. Int J Cancer, 2020, 147(2): 317-330.
14 FRACANZANI A L, CONTE D, FRAQUELLI M, et al. Increased cancer risk in a cohort of 230 patients with hereditary hemochromatosis in comparison to matched control patients with non-iron-related chronic liver disease[J]. Hepatology, 2001, 33(3): 647-651.
15 LLOVET J M, KELLEY R K, VILLANUEVA A, et al. Hepatocellular carcinoma[J]. Nat Rev Dis Primers, 2021, 7(1): 6.
16 ZUCMAN-ROSSI J, VILLANUEVA A, NAULT J C, et al. Genetic landscape and biomarkers of hepatocellular carcinoma[J]. Gastroenterology, 2015, 149(5): 1226-1239.e4.
17 CHIANG D Y, VILLANUEVA A, HOSHIDA Y, et al. Focal gains of VEGFA and molecular classification of hepatocellular carcinoma[J]. Cancer Res, 2008, 68(16): 6779-6788.
18 H?NZELMANN S, CASTELO R, GUINNEY J. GSVA: gene set variation analysis for microarray and RNA-seq data[J]. BMC Bioinformatics, 2013, 14: 7.
19 RITCHIE M E, PHIPSON B, WU D, et al. Limma powers differential expression analyses for RNA-sequencing and microarray studies[J]. Nucleic Acids Res, 2015, 43(7): e47.
20 WU T, HU E, XU S, et al. clusterProfiler 4.0: a universal enrichment tool for interpreting omics data[J]. Innovation (Camb), 2021, 2(3): 100141.
21 ZHANG X F, SMITS A H, VAN TILBURG G B, et al. Proteome-wide identification of ubiquitin interactions using UbIA-MS[J]. Nat Protoc, 2018, 13(3): 530-550.
22 DAS B, SENAPATI S. Immunological and functional aspects of MAGEA3 cancer/testis antigen[J]. Adv Protein Chem Struct Biol, 2021, 125: 121-147.
23 YUASA T, OKAMOTO K, KAWAKAMI T, et al. Expression patterns of cancer testis antigens in testicular germ cell tumors and adjacent testicular tissue[J]. J Urol, 2001, 165(5): 1790-1794.
24 HIROHASHI Y, TORIGOE T, TSUKAHARA T, et al. Immune responses to human cancer stem-like cells/cancer-initiating cells[J]. Cancer Sci, 2016, 107(1): 12-17.
25 HYMAN D M, TAYLOR B S, BASELGA J. Implementing genome-driven oncology[J]. Cell, 2017, 168(4): 584-599.
26 LIU S Z, MIAO M S, KANG L. Upregulation of MAD2L1 mediated by ncRNA axis is associated with poor prognosis and tumor immune infiltration in hepatocellular carcinoma: a review[J]. Medicine (Baltimore), 2023, 102(2): e32625.
27 LI Q, TONG D D, JING X T, et al. MAD2L1 is transcriptionally regulated by TEAD4 and promotes cell proliferation and migration in colorectal cancer[J]. Cancer Gene Ther, 2023, 30(5): 727-737.
28 JIANG W J, YANG X, SHI K H, et al. MAD2 activates IGF1R/PI3K/AKT pathway and promotes cholangiocarcinoma progression by interfering USP44/LIMA1 complex[J]. Oncogene, 2023, 42(45): 3344-3357.
29 WANG L, GUO B, WANG R W, et al. Inhibition of cell growth and up-regulation of MAD2 in human oesophageal squamous cell carcinoma after treatment with the Src/Abl inhibitor dasatinib[J]. Clin Sci (Lond), 2012, 122(1): 13-24.
30 JIANG H. The complex activities of the SET1/MLL complex core subunits in development and disease[J]. Biochim Biophys Acta Gene Regul Mech, 2020, 1863(7): 194560.
31 CHEN X, XIE W B, GU P, et al. Upregulated WDR5 promotes proliferation, self-renewal and chemoresistance in bladder cancer via mediating H3K4 trimethylation[J]. Sci Rep, 2015, 5: 8293.
32 ZHANG J T, ZHOU Q H, XIE K J, et al. Targeting WD repeat domain 5 enhances chemosensitivity and inhibits proliferation and programmed death-ligand 1 expression in bladder cancer[J]. J Exp Clin Cancer Res, 2021, 40(1): 203.
Options
Outlines

/

〈 〉